TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29617758
Drug: Headgear (HG)
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headgear (HG) treatment
Study: 19501822
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withania somnifera treatment
Study: 18539917
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (targeting glycated hemoglobin level below 6.0%)
Study: 18539917
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (targeting glycated hemoglobin level from 7.0 to 7.9%)
Study: 16038713
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg plus acetylsalicylic acid 75 mg
Study: 16038713
Drug: Extended-release dipyridamole
Normalized name: ASPIRIN 25 mg / DIPYRIDAMOLE 200 mg ORAL CAPSULE, EXTENDED RELEASE [ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release dipyridamole 200 mg plus acetylsalicylic acid 25 mg
Study: 10090427
Drug: Loading-dose metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading-dose metrifonate (100 mg or 150 mg for 2 weeks, then 50 mg for 4 weeks)
Study: 10090427
Drug: No-loading-dose metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-loading-dose metrifonate (50 mg for 6 weeks)
Study: 10090427
Drug: Loading-dose metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading-dose metrifonate
Study: 10090427
Drug: No-loading-dose metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-loading-dose metrifonate
Study: 8539322
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) and (100 mg)
Study: 2404388
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of streptokinase
Study: 6356901
Drug: Labetalol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol alone (100 to 1,200 mg twice a day)
Study: 6356901
Drug: Labetalol in
Normalized name: labetalol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol in combination with a diuretic
Study: 6356901
Drug: Labetalol (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (with or without diuretic)
Study: 31783766
Drug: Pelvic intensity‐modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic intensity‐modulated radiation therapy (IMRT) of 50 Gy/25Fx concurrently with capecitabine and oxaliplatin (Arm A)
Study: 27039894
Drug: Light‐emitting diode‐mediated‐photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT) applied with an energy density of 20 mW/cm2 for 21 successive days (20 minutes per day) over the movement of canine teeth.
Study: 27039894
Drug: Light‐emitting diode‐mediated‐photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT)
Study: 24215032
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) injections (1.25 mg/0.05 mL)
Study: 22504600
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral periodic presumptive treatment (PPT; 2 g metronidazole + 150 mg fluconazole)
Study: 17470024
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine spray
Study: 15533734
Drug: C12 peptide
Normalized name: C12:0
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C12 peptide with higher dose of alginic acid (1754 mg)
Study: 11973116
Drug: Telephone interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone interventions (two telephone contacts in addition to treatment as usual)
Study: 11973116
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (no telephone interventions)
Study: 9717819
Drug: 1.5 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/m2 9‐AC p.o. on day 1
Study: 9717819
Drug: 1.0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/m2 9‐AC i.v. on day 8
Study: 1971599
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tertatolol
Study: 2573371
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tertatolol with 1 g aspirin
Study: 3279
Drug: L-prolyl-Lleucyl-glycine amide
Normalized name: L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide
DrugBank: Dusquetide (DB11879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-prolyl-Lleucyl-glycine amide (PLG)
Study: 27986405
Drug: 1-h post-load
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h post-load plasma glucose <155 mg/dl
Study: 27986405
Drug: 1-h post-load
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h post-load plasma glucose ≥155 mg/dl
Study: 23670707
Drug: Canagliflozin 50
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 50 mg/day
Study: 31001673
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg/day
Study: 19545297
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 2 times per week
Study: 19545297
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 3 times per week
Study: 19545297
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 5 times per week
Study: 19545297
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 7 times per week
Study: 1475090
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of 1% acetylcholine chloride
Study: 6397852
Drug: Flunarizine 5
Normalized name: flunarizine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 5 mg b.i.d. during double-blind, cross-over medication period
Study: 6397852
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during double-blind, cross-over medication period
Study: 30725387
Drug: Non-selective antimuscarinic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective antimuscarinic drugs (trospium chloride, tolterodine tartrate, fesoterodine fumarate, propiverine hydrochloride)
Study: 30725387
Drug: Selective antimuscarinic
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective antimuscarinic drugs (darifenacin hydrobromide, solifenacin succinate, oxybutynin hydrochloride)
Study: 29663714
Drug: Mirogabalin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (10-40 mg single dose; 10, 15 mg twice a day repeated doses)
Study: 27333407
Drug: 6.6 g
Normalized name: FERROUS SULFATE 76.6 g in 454 g TOPICAL POWDER [Hemostat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.6 g Fortetropin supplementation
Study: 27333407
Drug: 19.8 g
Normalized name: DIMETHICONE 19.8 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19.8 g Fortetropin supplementation
Study: 25697893
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (O3FAs) - 2 capsules daily containing 180mg EPA and 120mg DHA for 3 months
Study: 25697893
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2 capsules of olive oil daily for 3 months
Study: 20578379
Drug: Vessel pricking
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vessel pricking therapy
Study: 6219455
Drug: Prednisone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (oral administration)
Study: 19002265
Drug: cisplatin-based second-line
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin-based second-line therapy
Study: 16877897
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) - fluoxetine or paroxetine (20 mg/day)
Study: 10827368
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 to 2.5 mg/kg)
Study: 1629506
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (ALB) with inhaled beclomethasone dipropionate (BDP)
Study: 1629506
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (ALB) with oral theophylline (THEO)
Study: 1629506
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (ALB), inhaled BDP, and oral THEO
Study: 6333247
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose mediastinal radiation
Study: 6333247
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy and radiotherapy (without low dose mediastinal radiation)
Study: 6333247
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (combination chemotherapy and radiotherapy)
Study: 24327173
Drug: Single eye-drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single eye-drop containing 0.0175, 0.175, or 0.7 μg rhNGF
Study: 24327173
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose of rhNGF eye drops three times a day for 1 day (total daily dose 2.1, 6.3, or 18.9 μg)
Study: 24327173
Drug: Multiple ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose of rhNGF eye drops three times a day for 5 days (total dose 10.5, 31.5, or 94.5 μg)
Study: 22364387
Drug: 12 week
Normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week exercise program including aerobic and strengthening exercises, conducted between 20 and 36 weeks of pregnancy, with one weekly group session led by physiotherapists and home exercises encouraged twice a week
Study: 15753847
Drug: Higher C2
Normalized name: Gentamicin C2
DrugBank: Gentamicin C2 (DB17884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher C2 target range (1,000-1,200 ng/mL for months 4-6 and 800-1,000 ng/mL for months 7-12)
Study: 15753847
Drug: Lower C2
Normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower C2 target range (800-1,000 ng/mL for months 4-6 and 600-800 ng/mL for months 7-12)
Study: 10559813
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of normal saline (NS)
Study: 10559813
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of lactated Ringer's solution (LR)
Study: 10559813
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of lactated Ringer's solution with 5% dextrose (D5LR)
Study: 2361193
Drug: Pilocarpine gel
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine gel
Study: 3377382
Drug: Pilocarpine 4%
Normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 4% solution
Study: 22110164
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% solution
Study: 22882084
Drug: Start For
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start For Life treatment (30 minutes daily of structured physical activity with behavioral and self-regulatory skills training)
Study: 24114718
Drug: Start For
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start For Life treatment
Study: 21598057
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (target 4.4‐6.1 mmoL·L(‐1) or 80‐110 mg·dL(‐1))
Study: 21598057
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose control (target 10‐11.1 mmoL·L(‐1) or 180‐200 mg·dL(‐1))
Study: 16685055
Drug: Soymilk (71.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk (71.6 mg isoflavones from 706 mL soymilk/d)
Study: 16685055
Drug: Supplement (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (70 mg isoflavones in a supplement plus 706 mL cow milk/d)
Study: 16685055
Drug: Control (706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (706 mL cow milk/d plus a placebo supplement)
Study: 11780680
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ) 60 mg orally twice daily for 12 weeks
Study: 23453459
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg/day for 14 days)
Study: 18371034
Drug: Surfactant replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant replacement therapy (bovine lung surfactant extract) with standard treatment for RDS
Study: 18371034
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for RDS without surfactant therapy
Study: 14519175
Drug: Bupropion (sustained-release)
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion (sustained-release)
Study: 10949981
Drug: Gemifloxacin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (320 mg once-daily for 5 days)
Study: 10949981
Drug: Amoxicillin/clavulanate (500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (500/125 mg three-times daily for 7 days)
Study: 9171971
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) and resistance exercise
Study: 3769187
Drug: Intravenous dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dipyridamole (0.24 mg/kg/hr)
Study: 29071914
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group receiving estradiol valerate (1 mg/day for 3 weeks, followed by a week of rest, then 1 mg/day and medroxyprogesterone 17-acetate (8 mg/day) for 10 days).
Study: 18602688
Drug: Vitespen (HSPPC-96);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitespen (HSPPC-96); administered intradermally once a week for 4 weeks, then every 2 weeks until vaccine depletion
Study: 18602688
Drug: Vitespen (HSPPC-96);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitespen (HSPPC-96); administered intradermally
Study: 16007029
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n=18)
Study: 12192554
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy with doses of 150 Gy
Study: 12192554
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy with doses of 300 Gy
Study: 12192554
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy with target dose of 256 Gy
Study: 2967184
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg once daily
Study: 31009768
Drug: 1 mm
Normalized name: PhaSeal Protector, 21 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mm allograft bone particles (ABP) augmentation in groups A1 and A2
Study: 31009768
Drug: Full (100%)
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full (100%) trajectory augmentation with 1 mm ABP in groups B1 and B2
Study: 20163941
Drug: Comprehensive lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive lifestyle intervention (L)
Study: 15585768
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract supplement
Study: 11723089
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diuretics and/or beta-blockers)
Study: 8995946
Drug: Citrucel, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrucel, 1 tablespoon twice daily
Study: 8995946
Drug: Pectin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin, 1 tablespoon twice daily
Study: 8515979
Drug: Controlled-release ibuprofen
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release ibuprofen 600 mg
Study: 8515979
Drug: Regular ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular ibuprofen 200 mg (3 doses)
Study: 8515979
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg (3 doses)
Study: 30809700
Drug: BetterStim sacral
Normalized name: Boswellia sacra whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: BetterStim sacral neuromodulation system (treatment group)
Study: 19921102
Drug: Glycoprotein IIb-IIIa
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb-IIIa inhibitors with Drug-Eluting Stents (DES)
Study: 19921102
Drug: Glycoprotein IIb-IIIa
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb-IIIa inhibitors with Bare Metal Stents (BMS)
Study: 18570578
Drug: Cefoperazone-sulbactam (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone-sulbactam (2-8 g/day)
Study: 18570578
Drug: Ceftazidime-amikacin-metronidazole (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime-amikacin-metronidazole (2-6 g/day, 15 mg/kg/day, 500 mg three times daily)
Study: 15845094
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion (0.5 M, 5 mL/kg body weight)
Study: 27415
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl infusion
Study: 10064170
Drug: Oral isoprinosine
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isoprinosine
Study: 10064170
Drug: Oral isoprinosine
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isoprinosine plus intraventricular alpha-interferon
Study: 8756801
Drug: Salmeterol (Sm)
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol (Sm) 50 micrograms twice daily
Study: 8756801
Drug: Salbutamol (Sb)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (Sb) 200 micrograms four times daily
Study: 1901200
Drug: Rifater (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifater (combined formulation)
Study: 28991149
Drug: Fluid Outpatient
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid Outpatient Rehabilitation Treatment (FORT)
Study: 28991149
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment planning
Study: 27256458
Drug: Preheated skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preheated skin disinfectant solution (36 °C)
Study: 27256458
Drug: Room-temperature skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room-temperature skin disinfectant solution (20 °C)
Study: 17239678
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with intracoronary injection of BM-SCs
Study: 17239678
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with combined application of BM-SCs
Study: 17239678
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment with intracoronary delivery of BM-SCs
Study: 17239678
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment with combined administration of BM-SCs
Study: 17239678
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment of AMI (control for all groups)
Study: 12032655
Drug: Combination beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination beta-carotene and vitamin E
Study: 10580202
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses at 2, 4, and 6 months
Study: 10580202
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose in the Swedish arm
Study: 10580202
Drug: Fourth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth dose in the US arm
Study: 10580202
Drug: Higher diphtheria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher diphtheria toxoid dose (25 Lf) in the Swedish arm
Study: 10580202
Drug: Higher tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher tetanus toxoid dose (7 Lf) in the Swedish arm
Study: 10580202
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the number of doses, prolonging intervals between doses, and increasing antigen amount
Study: 6357677
Drug: Fenoterol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.1 mg)
Study: 29117618
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil omega-3 fatty acids (1,000 mg, twice a day for 12 weeks)